Charles Elliott Sigal's Net Worth
$293 Thousand
Who is Charles Elliott Sigal?
Charles Elliott Sigal does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Adaptimmune Therapeutics PLC, Vir Biotechnology, Inc., Surface Oncology, Inc., and ALNYLAM PHARMACEUTICALS, INC..
SEC CIK
Charles Elliott Sigal's CIK is 0001661908
Past Insider Trading and Trends
2023 was Charles Elliott Sigal's most active year for acquiring shares with 8 total transactions. Charles Elliott Sigal's most active month to acquire stocks was the month of April. 2023 was Charles Elliott Sigal's most active year for disposing of shares, totalling 2 transactions. Charles Elliott Sigal's most active month to dispose stocks was the month of August. 2023 saw Charles Elliott Sigal paying a total of $246,339.75 for 964,852 shares, this is the most they've acquired in one year. In 2023 Charles Elliott Sigal cashed out on 159,089 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Adaptimmune Therapeutics PLC (ADAP) Snapshot price: $1.26
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 11
| |||
Form 4
| +5.02% | 15K |
$1.56 | $23,400.00 | 314.1K |
May 19
| |||
Form 4
| +17.71% | 45K |
$1.53 | $68,700.00 | 299.1K |
May 16 - May 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Vir Biotechnology, Inc. (VIR) Snapshot price: $9.125
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +61.63% | 6.03K |
—
|
—
| 15.81K |
May 22
| |||
Form 4
| +33.33% | 2.5K |
$22.73 | $56,815.50 | 10K |
Scheduled
|
Mar 1
| ||
Form 4
| +50.00% | 2.5K |
$24.96 | $62,395.50 | 7.5K |
Scheduled
|
Jan 5
| ||
Form 4
|
∞
| 5K |
$25.43 | $127,128.75 | 5K |
Scheduled
|
Jan 3 - Jan 4
| ||
Form 4
| +189.83% | 6.41K |
—
|
—
| 9.78K |
May 23
| |||
Form 4
|
∞
| 3.37K |
—
|
—
| 3.37K |
May 21
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Jul 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Surface Oncology, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -45.45K |
—
|
—
|
0
|
Sep 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 2
| |||
Form 4
|
∞
| 45.45K |
—
|
—
| 45.45K |
Apr 23
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ALNYLAM PHARMACEUTICALS, INC. (ALNY) Snapshot price: $168.935
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||